Effects of Granulocyte Colony-Stimulating Factor in Lung Cancer Patients
Author Information
Author(s): M.H. Bronchud, M.R. Potter, G. Morgenstern, M.J. Blasco, J.H. Scarffe, N. Thatcher, D. Crowther, L.M. Souza, N.K. Alton, N.G. Testa, T.M. Dexter
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester
Hypothesis
Can recombinant human granulocyte colony-stimulating factor (rhG-CSF) improve neutrophil counts and reduce infection rates in patients undergoing chemotherapy for small cell lung cancer?
Conclusion
The study found that rhG-CSF significantly increased peripheral neutrophil counts and reduced the incidence of infections in patients receiving chemotherapy.
Supporting Evidence
- All 12 patients responded to rhG-CSF with a specific increase in peripheral neutrophils.
- The number of infective complications requiring i.v. antibiotics was significantly lower during rhG-CSF treatment.
- Bone marrow cellularity increased by 20% after rhG-CSF infusion.
- Neutrophil mobility and phagocytic functions were normal after treatment with rhG-CSF.
- The median survival of patients with advanced small cell lung cancer was 8 months.
Takeaway
This study shows that a special medicine called rhG-CSF helps cancer patients by making their blood have more white blood cells, which fight infections.
Methodology
Twelve patients with small cell lung cancer received rhG-CSF via continuous infusion, and various blood and bone marrow tests were conducted before and after treatment.
Potential Biases
Potential biases may arise from the small sample size and the lack of a control group.
Limitations
The study had a small sample size and was limited to patients with small cell lung cancer.
Participant Demographics
All participants were patients with advanced small cell lung cancer.
Statistical Information
P-Value
p=0.028
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website